ArticleInternational journal of molecular and cellular medicine2025
Potential Protective Effects of Cerium Oxide Nanoparticles on Ultraviolet-B Irradiated Fibroblast Cells.
Article in International journal of molecular and cellular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Increased environmental ultraviolet-B (UVB) exposure stimulates reactive oxygen species (ROS) overproduction, disrupts cellular redox balance, and contributes to skin disorders. Antioxidants inhibit autoxidation by neutralizing or suppressing free radicals. Certain nanomaterials, like cerium oxide nanoparticles (CNPs), function as antioxidants under specific conditions. Through their redox and catalytic properties, CNPs scavenge ROS, mitigate oxidative damage, and may help prevent skin injuries. While most research targets ionizing radiation, studies exploring CNPs under non-ionizing UVB remain limited. To address this, the study evaluates their photochemoprotective effects in UVB-exposed L929 fibroblasts. The 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT), cupric ion reducing antioxidant capacity (CUPRAC), dichloro-dihydro-fluorescein diacetate (DCFH-DA), and annexin V/propidium iodide (annexin V/PI) assays were used to evaluate cell viability, oxidative stress, and apoptosis. Cell viability was assessed using the MTT assay at CNP concentrations of 10, 50, and 100 μM and UVB intensities of 150-900 mJ/cm², selected based on prior physiologically relevant in vitro studies. At 600 mJ/cm² UVB, cell viability decreased by 45% (MTT assay). Treatment with 50 μM CNP significantly increased total antioxidant capacity relative to untreated controls (CUPRAC assay, p = 0.0018). CNP and UVB effects on ROS production and apoptosis were evaluated separately and in combination using DCFH-DA and annexin V/PI assays. Results show that pretreatment with CNPs before UVB radiation impedes cell apoptosis and reduces ROS, suggesting that CNPs mitigate UVB-induced oxidative damage in L929 cells by restoring oxidative balance through their redox activity and ROS-scavenging properties. These findings indicate CNP-based interventions may offer therapeutic strategies against UVB-induced skin and related disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.